Trinity Biotech (TRIB) FCF Margin (2009 - 2024)
Trinity Biotech (TRIB) posted quarterly FCF Margin of 23.59% for Q4 2024, up 1942.0% year-on-year from 1.16% in Q1 2024, and up 195.43% on a QoQ basis from 24.72% in Q2 2024.
Trinity Biotech (TRIB) FCF Margin (2009 - 2024) Analysis & Trends
Trinity Biotech (TRIB) has reported FCF Margin for 14 consecutive years, with 23.59% the latest figure, recorded in Q4 2024.
- Quarterly FCF Margin rose 1942.0% year-over-year to 23.59% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.29% (up 1105.0% YoY) and the FY2025 annual result came in at 13.74%, down 463.0% from the prior year.
- FCF Margin climbed to 23.59% in Q4 2024 per TRIB's latest filing, from 24.72% in the prior quarter.
- Over the last five years, FCF Margin for TRIB reached as high as 23.59% in Q4 2024 and fell as low as 51.29% in Q2 2023.
- A 4-year average of 0.41% and a median of 0.44% in 2021 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin plunged 5129 bps — and 2024, when it surged 2658 bps.
- Year by year, FCF Margin stood at 22.94% in 2021, then dropped by 23 bps to 17.56% in 2022, then tumbled by 76 bps to 4.17% in 2023, then soared by 466 bps to 23.59% in 2024.
- According to Business Quant data, FCF Margin over the past three periods registered 23.59%, 24.72%, and 0.02% for Q4 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Trinity Biotech | 93,750.00 | -5.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 23.59% |
| Jun 30, 2024 | -24.72% |
| Mar 31, 2024 | -0.02% |
| Dec 31, 2023 | 4.17% |
| Sep 30, 2023 | 0.87% |
| Jun 30, 2023 | -51.29% |
| Mar 31, 2023 | -0.04% |
| Dec 31, 2022 | 17.56% |
| Sep 30, 2022 | 2.04% |
| Jun 30, 2022 | 0.00% |
| Dec 31, 2021 | 22.94% |
| Jun 30, 2021 | 0.00% |
| Jun 30, 2018 | 6.95% |
| Jun 30, 2017 | 13.25% |
| Dec 31, 2016 | -11.87% |
| Dec 31, 2015 | -11.34% |
| Dec 31, 2014 | -13.74% |
| Dec 31, 2013 | -11.71% |
| Dec 31, 2012 | -11.75% |
| Dec 31, 2011 | -13.26% |